 The tumor antigenic peptides Melan-AMart-1 EAA and ELA and Tyrosinase YMD are combined with two drugs in this study, both of which are known to enhance immune responses: first, CpG 7909 oligodeoxynucleotides, and second, Montanide ISA-51. 